$A FDA approval expands the PD-L1 IHC 28-8 pharmDx indication to Esophageal Squamous Cell Carcinoma, Gastric/GEJ, and Esophageal Adenocarcinoma, unlocking an expanded addressable oncology diagnostics market and strengthening the product portfolio. The regulatory milestone signals increased adoption potential across ESCC, GEJ, and esophageal cancer patients, with the 28-8 assay serving as a clinically relevant companion diagnostic and potential near-term revenue impact. #Biotech #FDA